IBRX Stock — ImmunityBio Inc.: Cash, EV, Pipeline

Share price

$8.48

Market cap

$8,987.4M

Cash

$357.4M

Enterprise value

$8,630.9M

Balance sheet

Cash	$357.4M
Debt	$0.9M
Net cash	$356.5M
Enterprise value	$8,630.9M
Basic shares	1,053.2M shares
Fully diluted shares	1,275.5M shares
Fully diluted market cap	$10,816.0M
Cash per share	$0.34

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading IBRX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Sep 23, 2026	Anktiva	Phase 2	Long COVID; Long COVID Syndrome; Long Covid 19	—
Nov 12 - Dec 24	N-803 (IL-15 Superagonist)	Phase 2	Long COVID	—
Dec 13, 2026 - Jan 24, 2027	N-803 and BCG	Phase 2	Non-muscle Invasive Bladder Cancer (NMIBC)	—
Jun 12 - Jul 24	Gemcitabine	Phase 2	Platinum-resistant Ovarian Cancer	—
Jul 6 - Aug 17	CD19 t-haNK- IV Administration	Phase 2	Relapsed B-Cell Non Hodgkin Lymphoma	—
Sep 14 - Oct 26	Nogapendekin alfa inbakicept (NAI)	Phase 2	Sepsis; Septic Shock; Lymphopenia	—
Oct 14 - Nov 25	IBRX-042	Phase 1	HPV-Related Carcinoma	—
Nov 12 - Dec 24	CD19 t-haNK	Phase 1	Non-Hodgkin Lymphoma Refractory/ Relapsed	—
Nov 23, 2027 - Jan 4, 2028	Nogapendekin alfa inbakicept (NAI)	Phase 2	Sepsis; Septic Shock	—
Jan 12 - Feb 23	CD19 t-haNK- IV Administration	Phase 2	Relapsed B-Cell Non-Hodgkin Lymphoma	—
Mar 14 - Apr 25	Intravesical Recombinant Mycobacterium (rMBCG)	Phase 2	NMIBC	—
Oct 13 - Nov 24	N-803	Phase 3	NSCLC Stage IV	—
Feb 11 - Mar 25	Durvalumab (Cohort 1-3)	Phase 2	Urothelial Carcinoma; Bladder Cancer	—
Oct 12 - Nov 23	N-803	Phase 2	Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Urothelial Carcinoma	—
Feb 11 - Mar 25	Bevacizumab	Phase 2	Glioblastoma	—
Feb 11 - Mar 25	Nogapendekin Alfa Inbakicept (NAI)	Phase 2	HPV-Positive Oropharyngeal Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma; Head and Neck Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ANKTIVA

Approved · Active Modality: IL-15 receptor superagonist antibody-cytokine fusion protein

Aliases N-803

Target IL-15 receptor

Partnerships Serum Institute (partnership); BeOne (collaboration, Jan 2025); international partners for EU and Middle East/North Africa commercialization

Indications

BCG-unresponsive NMIBC with CIS (with or without papillary tumors) (Approved)
BCG-unresponsive NMIBC with papillary tumors without CIS (Phase 3)
BCG-naive NMIBC CIS (with or without papillary tumors) (Phase 2)
NSCLC (Stage not disclosed)
Indolent non-Hodgkin lymphoma incl. Waldenstrom macroglobulinemia (Stage not disclosed)
Colorectal cancer (Stage not disclosed)

Catalysts

— January 6, 2027
— 2026

Status note FDA approved Apr 2024 (J-code Jan 2025); approved/authorized in 5 jurisdictions (34 countries). NCI evaluating ANKTIVA in Lynch syndrome cancer prevention study.

PD-L1 t-haNK

Phase 2 · Active Modality: CAR-NK cell therapy (PD-L1 targeted)

Target PD-L1

Indications

Recurrent glioblastoma (with ANKTIVA) (Phase 2)
Multiply relapsed locally advanced/metastatic pancreatic cancer (with ANKTIVA) (Phase 2)

Status note ANKTIVA + PD-L1 t-haNK: recurrent GBM Phase 2 complete, registrational trial planned; pancreatic cancer Phase 2 (FDA RMAT designation for ANKTIVA + PD-L1 t-haNK with chemo/radiotherapy for lymphopenia reversal and treatment of multiply relapsed pancreatic cancer).

Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	N-803
Lead indication	NSCLC Stage IV
Lead phase	Phase 3
Active trials	21
Collaborator trials	6

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06745908	Phase 3	Recruiting	Sponsor	IBRX	—	NSCLC Stage IV	—
NCT03022825	Phase 3	Active, not recruiting	Sponsor	IBRX	—	Bladder Cancer	—
NCT02138734	Phase 2	Active, not recruiting	Sponsor	IBRX	—	Non-muscle Invasive Bladder Cancer	—
NCT07108036	Phase 2	Recruiting	Sponsor	IBRX	—	Long COVID	—
NCT06829823	Phase 2	Not yet recruiting	Sponsor	IBRX	—	Non-muscle Invasive Bladder Cancer (NMIBC)	—
NCT06710288	Phase 2	Recruiting	Sponsor	IBRX	—	Platinum-resistant Ovarian Cancer	—
NCT07125872	Phase 2	Recruiting	Sponsor	IBRX	—	Relapsed B-Cell Non Hodgkin Lymphoma	—
NCT07578558	Phase 2	Not yet recruiting	Sponsor	IBRX	—	Sepsis; Septic Shock; Lymphopenia	—
NCT07783789	Phase 2	Not yet recruiting	Sponsor	IBRX	—	Sepsis; Septic Shock	—
NCT07477366	Phase 2	Not yet recruiting	Sponsor	IBRX	—	Relapsed B-Cell Non-Hodgkin Lymphoma	—
NCT06800963	Phase 2	Recruiting	Sponsor	IBRX	—	NMIBC	—
NCT03228667	Phase 2	Active, not recruiting	Sponsor	IBRX	—	Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Urothelial Carcinoma	—

Sponsor-matched active trials from ClinicalTrials.gov (21 as sponsor, 6 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 27 active trials for ImmunityBio, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.